166 139

Cited 4 times in

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)

DC Field Value Language
dc.contributor.author김은영-
dc.date.accessioned2023-06-02T00:38:22Z-
dc.date.available2023-06-02T00:38:22Z-
dc.date.issued2022-12-
dc.identifier.issn1759-7706-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194319-
dc.description.abstractIntroduction: The PACIFIC study demonstrated that durvalumab consolidation therapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT). However, there was no clinical benefit in both PFS and OS in epidermal growth factor receptor (EGFR) mutation-positive patient groups in a post hoc exploratory analysis. Moreover, the clinical effects of immune checkpoint inhibitors (ICIs) in EGFR mutation-positive stage IV NSCLC were demonstrated to be poor. Personalized treatment according to the mutation status is also required in stage III NSCLC. Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is newly developed and approved for use in Korea. Methods: This prospective, open, single-arm, multicenter, phase II clinical trial aims to evaluate the efficacy and safety of lazertinib as a consolidative therapy after CCRT treatment in unresectable, EGFR mutation-positive NSCLC stage III patients. The primary endpoint of this study is PFS, and the secondary endpoints are OS, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM), and safety profiles. Discussion: Our study may extend the indications for third-generation EGFR-TKIs to treat patients with stage III NSCLC. Moreover, using this drug to treat stage III NSCLC would emphasize the value of mutation analysis and personalized medicine. Trial registration: ClinicalTrials.gov NCT05338619.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherWiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute-
dc.relation.isPartOfTHORACIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / genetics-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHConsolidation Chemotherapy-
dc.subject.MESHErbB Receptors / genetics-
dc.subject.MESHErbB Receptors / therapeutic use-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHLung Neoplasms* / genetics-
dc.subject.MESHMutation-
dc.subject.MESHPlatinum / therapeutic use-
dc.subject.MESHProspective Studies-
dc.subject.MESHProtein Kinase Inhibitors / therapeutic use-
dc.titleA phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJuwhan Choi-
dc.contributor.googleauthorJeong Eun Lee-
dc.contributor.googleauthorChang-Min Choi-
dc.contributor.googleauthorIn-Jae Oh-
dc.contributor.googleauthorKye Young Lee-
dc.contributor.googleauthorTae Won Jang-
dc.contributor.googleauthorSeung Hyeun Lee-
dc.contributor.googleauthorEun Young Kim-
dc.contributor.googleauthorDong Won Park-
dc.contributor.googleauthorSun Hyo Park-
dc.contributor.googleauthorSung Yong Lee-
dc.identifier.doi10.1111/1759-7714.14663-
dc.contributor.localIdA00811-
dc.relation.journalcodeJ02725-
dc.identifier.eissn1759-7714-
dc.identifier.pmid36259253-
dc.subject.keywordEGFR-
dc.subject.keywordchemoradiotherapy-
dc.subject.keywordconsolidation therapy-
dc.subject.keywordlazertinib-
dc.contributor.alternativeNameKim, Eun Young-
dc.contributor.affiliatedAuthor김은영-
dc.citation.volume13-
dc.citation.number23-
dc.citation.startPage3431-
dc.citation.endPage3435-
dc.identifier.bibliographicCitationTHORACIC CANCER, Vol.13(23) : 3431-3435, 2022-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.